Zimmer looking at Sintx for spine and total joints?


I've shown over and over and over again that your first sentence is just not true. Im guessing what youre saying about CTL is a partial truth, as in only part of the story, but i do not know the particulars. The sales of Si3N4 implants to date has been a live trial, or Real World Evidence trial, to establish long-term implant data all over the world, in the tens of thousands, while generating some revenue.

According to the following article, bioceramics/glasses are the future of ortho expected to overtake traditional metals and PEEK. There is no better bioceramic/bioglass that i am aware of than Si3N4.



https://finance.yahoo.com/news/global-orthopedic-biomaterials-market-size-080000374.html
Live trial? Do we look retarded? You don’t know this industry one bit. Try not and make it obvious if you’re gonna keep this act up.
 


Live trial? Do we look retarded? You don’t know this industry one bit. Try not and make it obvious if you’re gonna keep this act up.
Yes live trial, as in not a closed controlled study. A label you maybe more familiar with, Real World Evidence. When i said live trial, think of it like taking software live and then seeing how it actually performs for the masses as opposed to beta which is more of a controlled study akin to a clinical trial. Im sorry if you are overly sensitive to me using different labels to describe something.

RWE offers several advantages:​

  1. Broader Patient Populations: RWE includes data from a wide range of patients, including those with comorbidities or characteristics that might exclude them from clinical trials. This provides a more comprehensive understanding of treatment outcomes.
  2. Long-Term Insights: Since RWE captures data over extended periods, it can reveal the long-term effects and safety profiles of interventions.
  3. Diverse Treatment Settings: RWE encompasses various healthcare settings, from academic hospitals to community clinics, reflecting the full spectrum of patient care.
  4. Cost-Effectiveness: Conducting RWE studies is often more cost-effective and faster than running extensive clinical trials.

So again, Si3N4 implant sales to date have been to establish real world evidence across a diverse populace, in the tens of thousands, along with long-term data at this point as the implants have been implanted for over 15 years all while generating a degree of revenue. Controlled clinical studies, however, do not bring in any revenue, just burn cash. So you can see the advantage of this approach vs a standard clinical study, which Sintx did as well.
There was a small study in Australia that did a 30 year retrospective look at Si3N4 implants from the 80s, or almost 40 years ago now, with good success. This is something Zimmer should have looked for before diving into Trabecular Metal. Maybe had it waited for longer term data like Sintx has, then it wouldnt have suffered so many lawsuits connected to TM.
 


If you have to pay over 40% commission for anyone to use your product, there’s a problem there. I happen to know one of the only surgeons who use CTL Si3n4, and I can tell you it’s about the money, not the product. There’s huge problem when you’re paying out 10,000’s for one case and still can’t get anyone to sell your product. A HORRIBLE look for CTL currently. They don’t push the science, they push the commission. Real world talk.
 


Stryker coming out with their gold knee later this year. If they went pyro carbon and Gold then we can pretty much assume ceramic is a no go. Probably why spine dr’s won’t adopt its use either. Nobody wants to be the one with a broken shard of ceramic cutting a spinal cord in half. Ceramic has its known issues, that’s why Stryker went with other options, not many ceramic hip users left anyways. Smith and nephew has never promoted oxinium as a ceramic coating. They sell it as oxidized zirconium. A nickle free alternative. Never will they compare it to a ceramic or a coating. No no words in the industry. Everyone waiting to see this gold knee from Stryker.
 


Stryker coming out with their gold knee later this year. If they went pyro carbon and Gold then we can pretty much assume ceramic is a no go. Probably why spine dr’s won’t adopt its use either. Nobody wants to be the one with a broken shard of ceramic cutting a spinal cord in half. Ceramic has its known issues, that’s why Stryker went with other options, not many ceramic hip users left anyways. Smith and nephew has never promoted oxinium as a ceramic coating. They sell it as oxidized zirconium. A nickle free alternative. Never will they compare it to a ceramic or a coating. No no words in the industry. Everyone waiting to see this gold knee from Stryker.
Is there a documented incident of a Si3N4 spinal implant breaking & cutting a spinal cord in half? You're saying Ceramic like all ceramics are created equal and thats just not the case. Silicon Nitride is superior to ZTA for instance but not necessarily in regards to wear performance where they were fairly equal. Si3N4 extended the life of the liners however. The other component not widely discussed is the buildup of ZTA in the surrounding tissue with some potential to migrate to organs like the brain. Thats an issue with all the other materials as they are inflammatory, do not breakdown in the body and thus buildup in the tissue, and in regards to metals at least, are transported throughout the body to accumulate in its organs.

Yes even Silicon Nitride is not perfect. Its biggest drawback was its modulus of elasticity if i recall but 3D printing is supposed to fix that creating very precise highly porous implants. As Si3n4 is Biodegradable and enhances osseointregration as it breaks down, they could develop implants that are slowly replaced by the bone as it regrows...at least in regards to spine.
Oxinium is not Si3n4 nor does it have the benefits of Si3n4. Also, did Smith and Nephew even bother to develop a coating to market? Maybe thats why they never promoted it?
Gold is just another metal and as such it will experience issues with Hutchison Effect caused spontaneous fracturing, it'll amplify EM radiation causing problems for patients, it'll suffer corrosion issues, and it'll slowly poison patients just like any other metal with ions that traverse the body.

Sintx also has 3D printed PEEK/Si3N4 spine implants coming soon. The 2 year study should be coming to an end anytime during the next few months. Given managements mention of this tech in their recent update PR, im guessing results were good. Not a fan of PEEK but I see it and Sintx coating tech as a bridge to help transition the industry to full Si3N4 implants and fill gaps in places Si3n4 is not as effective. Same with metals, we will not likely see them completely transitioned away from as there are applications where the strength/durability are absolutely necesssary. In that case a Si3n4 coating could be applied to reduce corrosion (ion release) and potentially reduce spontaneous fracturing.

All the above aside, Sintx Si3N4 can be used in so many different applications outside of spine, arthroplasty, and dental. Cancer, wound care, catheters, PPE, neural implants, and so many other applications its crazy to consider them all. I do not know why Zimmer Biomet would not want to partner and eventually acquire the tech as its spent decades helping oversee its development. Sintx and its materials would help Zimmer Biomet diversify its revenue sources like no other company could. That is if ZB actually wants to continue as a public company and isnt looking to get acquired as another thread here suggests. With Arthur Higgins conenctions to the ADIA and Sintx connections to it via TVM, maybe a PE company will acquire both? They certainly have the money to invest over in the Middle East and it would be a way to further diversify away from their depence on Oil revenue.
 


I know of multiple revision cases of Si3n4 spine implants, 100%, all within a days drive of salt lake also. Amedica couldn’t sell spine for the life of them. We all know how they couldn’t sell it and fumbled hard and could only pay extreme % and surgeons out the back door. Now CTL in the same boat, can’t sell Si3n4 to new users and paying high% to get any out the door. I even know a Distributer paying surgeon cash money to use CTL Amedica products and you’re talking ZTA lol, which Zimmer actually sold. Amedica and CTL couldn’t sell Si3n4, now you want it to be Zimmers problem lol. All indications say Si3n4 can’t be sold without offering huge % and paying surgeons cash at end of year. Those are the facts of your precious Si3n4, it’s not sellable, as 10 years of trying can’t produce the revenue to cover making it. That’s the reality of sintx and CTL.
 


Well they & CTL have sold over 50k implants with about 50 adverse events in FDA MAUDE database. Most of those being an event around trying to place the implant.

Zimmer wouldnt have to pay the same premiums as small companies tend to I can tell you that much. I wonder if you're even a rep for a company because even I know big companies do not have to pay what the little guys do. Completely different negotiating positions.

Im not the only one that believes Si3n4 is the future.

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm
 


You don’t know anything about this business. It is brutally obvious. You probably haven’t sold any med device and have no idea what you are talking about when it comes to actually selling. Fact is, nobody wants to buy sintx, its tiny market cap, I’ve seen dozens of little companies get scooped up and products shelved, sintx doesn’t even get that treatment, they became the joke of the industry on their own. Never seen a company waste so much money on nothing. Investors should be upset, I would if I spent 10 years promising every person that Amedica/sintx is an investors dream. Only to have every single person except those that were insider trading lose everything they invested. GONE. That’s the inside you are on, the side that’s taken everything from everyone and not even let them ask a question about how their money was used and lost. 10 years of sintx stealing investors money on lies. Facts.
 


Do the sales reps cause the inventory issues and cut R&D expense? Do the sales reps spend 65% of FCF on share buybacks? Do the sales reps make $1B+ acquisitions and screw up the integration (LDR, P28)?

Larger companies like Zimmer Biomet that cut R&D investment look for companies with tech to acquire. At least thats what J&J does.

In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.

Quote Sources:
ZBH Looking To Be Acquired??
https://d3.harvard.edu/platform-rctom/submission/a-family-of-companies-johnson-johnson/
 


Same story told for 7 years now. What happened to your website dedicated to the great Zimmer buyout theory? Took that down like a dog with his tail between his legs and never mentioned that again. Nobody wants this crap company, it’s got a stain for years that doesn’t come out. Scott Mosier still trying to wash sintx year after year with the same results. Stained. Insanity is doing the same thing over and over expecting different results. Scott Mosier aka Boston is an insane, narcissistic compulsive liar who now suffers from Paranoid schizophrenia as well. (Looking out the blinds at every car that drives by, baby goats and more craziness now). Get some real help, this is getting sad to see you fall apart like this.
 


Sintx follows Zimmer Biomet in acquiring Foot/Ankle IP and improve its 3D printing capability. Maybe this will help enhance Paragon 28's tech one day?

SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market​

Around 2009 I was a member of a design team for Total Joint replacement. We had a specific interest in alternative bearings/materials and were working with a company that had commercialization rights to SiN. We saw, firsthand, the challenges with subtractive technology and machining of mature ceramics. These issue were certain impediments to the business case with these materials. For practical reasons we shelved those opportunities. In the meantime, a good friend and eventual SiNaptic Co-Founder went to work with a company commercializing SiN, mostly with spinal fusion cages. He, too, was disheartened by the existing limitations of the production. We kept in touch on the topic…..Fast forward a decade, and companies like Lithoz were successfully 3D printing ceramics to scale, but with a mostly wide open market/customer base in all the applicable, end-market scenarios. Therein, was the inspiration.
Some more insight into the struggles Sintx and CTL-Amedica faced scaling production of Si3N4 based implants. Sinaptic was founded in 2022 and was looking to 3D printing as a solution for production issues. It would appear Dr Scheer worked with Sintx early on while his friend and Sinaptic Co-founder worked for CTL-Amedica.

Quote Sources:
SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market
Interview with Dr. Bryan Scheer: From Bedside To SiNAPTIC Technologies
 


Comparing Zimmers Paragon purchase @1.2 billion dollars to Sintx purchase of SiNAPTIC for some sintx shares is quite the leap. Keep showing everyone your intelligence, it’s amazing.
 


Comparing Zimmers Paragon purchase @1.2 billion dollars to Sintx purchase of SiNAPTIC for some sintx shares is quite the leap. Keep showing everyone your intelligence, it’s amazing.
Thats not what i was doing. I was talking about follow the leader in this case. In the past both Zimmer and Sintx, when it was Amedica, both began the process/divested their spine divisions. I just think its interesting that Sintx emulates Zimmer. That was my point. Sorry if that was confusing for you.

Sintx follows Zimmer Biomet in acquiring Foot/Ankle IP and improve its 3D printing capability

Correction, it appears Sintx only acquired Sinaptic Surgical assets/talent and it looks like the 3D printers are part of a different subsidiary Sinaptic Tech. I honestly do not know why Sintx acquired implant IP when it doesnt currently have a direct to sales model?

SiNAPTIC Technologies provides R&D and prototyping all the way to scaled OEM manufacturing, whereas SiNAPTIC Surgical is currently undergoing FDA approval to become a fully integrated original medical device producer.
 


When sintx was Amedica a group of us told them to make small foot anchors as a starting point and something to sell. They could have had a great thing going but choose more spine products and then couldn’t sell anything. That was 7 years ago probably, sintx now wants to play foot sales as Sinaptic was in the same position as Amedica was with spine. Unsellable. Sintx buying competition in markets they have no products in. They need to settle down the talking points as it’s making them look dumb as usual with a whole new leadership team doing the talking. We all see how crazy they are, they need money soon, something’s gotta happen. If they buyback shares and immediately sell more what the hell are they doing?
 


they need money soon, something’s gotta happen. If they buyback shares and immediately sell more what the hell are they doing?
If they bought back shares at an avg of say 2.50 and turned around and raised funds at 7.50+ then thats a smart move no?

With the new talent they acquired they likely increased their burnrate to 1.5+m a quarter so its true they could need raise funds Q4/Q1. That would especially be true if they are trying bring products to market with their partners...assuming of course those partners do not invest in Sintx. If thats the case there should be something to increase the value of the stock so Anson's family of funds can sell into the "pump". So far Anson's group of funds have subjected the stock to their usual 50% haircut from their buyin price. Next is the pump...whenever that will happen. Thats been the pattern to date. Under Honigblum leadership Sintx seems to be making moves to support their stockprice...finally.

Sintx has sold over 50k implants with about 15k or so with CTL-Amedica's help. We are coming up on 20 years since the first Sintx implant was implanted giving longterm data to support Si3N4 as an implantable material. The implants have performed well with very few adverse events. Zimmer Biomet has been behind the scenes of Sintx for the last 20 years or so. It obviously sees something worthwhile that it continues to help Sintx.

The future of ortho needs to go to Ceramics and away from metals as much as possible. In addition to spontaneously fracturing due to the Hutchison Effect, as i've already shown, metal implants release toxic ions into the body that collect in patient organs. That's slowly poisoning each and every patient. In addition to that, these heavy metals also amplify EM radiation causing greater dis-ease for patients. Not only because we are being exposed to more EM radiation from man-made sources like EVs and cell towers, but also because as the earths magnetic field contiues to weaken we are being exposed to natural EM radiation at the surface from the earth itself and from space. As the field weakens further more problems related to this will arise causing more disease for patients with metal implants. The solution is Si3N4 coating and/or complete replacement by bioceramics like Si3N4. To a lessor extent PEEK implants with Si3N4 imbued can be used in place of metals when necessary.
 


Sintx sold 35,000 implants and couldn’t make a profit. Talk about some cluster F of managment. Ask their old reps how sintx sales went and how much they paid their dr’s to use it.
 


The future of ortho needs to go to Ceramics and away from metals as much as possible. In addition to spontaneously fracturing due to the Hutchison Effect, as i've already shown, metal implants release toxic ions into the body that collect in patient organs. That's slowly poisoning each and every patient.

Toxicity, Irritation, and Allergy of Metal Implants: Historical Perspective and Modern Solutions
While titanium is traditionally considered bioinert, emerging evidence suggests that under certain conditions, even inert metals can induce adverse biological effects. Furthermore, this review emphasizes the role of oxidative stress, illustrating how metal ion release and systemic toxicity contribute to long-term health risks. It also uncovers the underappreciated genotoxic and cytotoxic effects of metal ions on cellular metabolism, shedding light on potential long-term repercussions. By integrating a rigorous methodological approach with an in-depth exploration of metal-induced biological responses, this paper offers a more nuanced perspective on the complex interplay between metal implants and human biology, advancing the discourse on implant safety and material innovation.
Future research should prioritize the development of advanced surface modifications, including nanotechnology-based coatings, to mitigate corrosion and reduce ion release.
These scientists believe coatings are necessary to reduce ion release due to the biological hazards these metals pose to human biology.

https://www.mdpi.com/2079-6412/15/3/361
 




He said coatings…. No wonder why sintx is in the crapper.
A coating is a bridge solution and Sintx has a patented (soon) method for applying Si3N4 to current materials. Coatings will reduce ion release, should reduce spontaneous fracturing, and EM amplification but it will not stop it. Not to mention imparting the various benefits Si3n4 already provides that current materials do not like enhanced osseointegration, encourages bone growth through releasing orthosilicic acid, & antimicrobial properties.
The only way to stop the problems with metal implants is by replacing all metal components. That said, 100% replacement will never be achieved. Thus, whenever possible metal components should be replaced with truly biocompatible materials like Si3N4. When metal components cannot be replaced, then apply a coating to reduce ion release. This will maximize reduction of biological harm while maintaining important structural integrity.

To me the coating solution, as i already indicated, is a bridge solution. It allows for the conversion of current implants, even already manufactured ones, without completely disrupting the industry. It allows for every level of stakeholder to become familiar with Si3N4 which should build trust for the material within the industry. Then over time, more patients will switch from metal coated implants to implants that are 100% Si3N4 or close to it. But hey, what do I know?

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for SINTX’s patent application no. 17/237,687, titled “Methods of Silicon Nitride Laser Cladding.”
The patent, expected to be issued soon, protects a revolutionary method for laser bonding bioactive silicon nitride to various biomedical implant substrates, including titanium, alumina, zirconia, and advanced polymers like PEKK. This breakthrough technology enhances the biological performance of these substrates by imparting silicon nitride’s superior osseointegration and bacterial resistance properties.​
These advancements not only open new opportunities in the biomedical field but also offer innovative pathways for upgrading existing devices with silicon nitride’s unmatched properties. Additionally, the coating method enables the refinishing of implants, enhancing their functionality and extending their usability—a significant advantage in today’s medical device market.

SINTX Technologies Secures Patent Allowance for Wide-Ranging Silicon Nitride Biomaterial Applications
 


Zimmer has the inside track to utilize Si3N4 products but it needs to get moving. Especially before another pandemic rears its head. Zimmer Biomet is in the weakest position of the major ortho companies during pandemics due to severe lack of diversification. Something its claimed it was going to rectify years ago, during Hanson's time, and still has not done so as far as I can tell.

COVIDs slowly getting worse, bird flu is getting worse but still isolated to animals. Bill Gates sees another pandemic within the next 4 years as 10-15% likely. Whether that is COVID 2.0 or a new(ish) virus. Trump seems hell bent on weakening the healthcare system even more which would mean the next pandemic could be more deadly and put a greater strain on hospitals and their employees.
 



Write your reply...